Colorectal liver metastases: Treat effectively up front and consider the borderline resectable

Journal of Clinical Oncology

Volumn 25, Issue 29, 2007, Pages 4524-4525

  Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IRINOTECAN; OXALIPLATIN;

BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; LIVER METASTASIS; LIVER RESECTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 35648985182     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1136     Document Type: Editorial

References (16)

1. Tomlinson JS, Jarnagin WS, De Matteo RP, et al: Actual ten-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575-4580, 2007
2. Jamison RL, Donohue JH, Nagorney DM, et al: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 132:505-510, 1997
3. Scheele J, Stang R, Altendorf-Hofmann A, et al: Resection of colorectal liver metastases. World J Surg 19:59-71, 1995
4. Adam R, Aloia T, Wicherts DA, et al: Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593-4602, 2007
5. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 8:347-353, 2001
6. Sobrero AF, Fehrenbacher L, Rivera F, et al: Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: The EPIC trial. Presented at Proc Am Assoc Cancer Res Annual Meeting, April 14-18, 2007, Los Angeles, CA
7. Hochster HS, Hart LL, Ramakrishnan PK: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-study. J Clin Oncol 24:148s, 2006 (suppl; abstr 3510)
8. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16:1311-1319, 2005
9. Charnsangavej C, Clary B, Fong Y, et al: Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 13:1261-1268, 2006
10. Karoui M, Penna C, Amin-Hashem M, et al: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1-7, 2006
11. Vauthey JN, Pawlik TM, Ribero D, et al: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072, 2006
12. Pawlik TM, Scoggins CR, Zorzi D, et al: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715-724, 2005
13. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520, 1996
14. Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818-825, 2004
15. Figueras J, Valls C, Rafecas A, et al: Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980-985, 2001
16. Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061, 2004